EcoDrugPlus

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSSTUG00000017793
Gene Symbol: PARP3
3 Cross references
194 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSSTUG00000021920
Gene Symbol: PORCNL
1 Cross references
191 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSSTUG00000011003
Gene Symbol: KCNMA1
3 Cross references
229 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSSTUG00000027806
Gene Symbol: KCNMA1
3 Cross references
226 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSSTUG00000009706
Gene Symbol: KCNMA1
3 Cross references
234 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSSTUG00000027222
Gene Symbol: KCNMA1
3 Cross references
235 Possible Orthologues:

Potassium Channel Subfamily K Member 3-Like

Ensembl ID : ENSSTUG00000043204
Gene Symbol: LOC115175007
3 Cross references
196 Possible Orthologues:

Potassium Channel Subfamily K Member 9-Like

Ensembl ID : ENSSTUG00000037630
Gene Symbol: LOC115173729
3 Cross references
212 Possible Orthologues:

Potassium Channel Subfamily K Member 9-Like

Ensembl ID : ENSSTUG00000021566
Gene Symbol: LOC115175747
3 Cross references
212 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSSTUG00000000888
Gene Symbol: KCNJ2
3 Cross references
197 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSSTUG00000045477
Gene Symbol: KCNJ2
3 Cross references
195 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSSTUG00000049217
Gene Symbol: KCNJ3
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).